112 related articles for article (PubMed ID: 23243020)
1. Midkine promotes neuroblastoma through Notch2 signaling.
Kishida S; Mu P; Miyakawa S; Fujiwara M; Abe T; Sakamoto K; Onishi A; Nakamura Y; Kadomatsu K
Cancer Res; 2013 Feb; 73(4):1318-27. PubMed ID: 23243020
[TBL] [Abstract][Full Text] [Related]
2. The neuronal differentiation factor NeuroD1 downregulates the neuronal repellent factor Slit2 expression and promotes cell motility and tumor formation of neuroblastoma.
Huang P; Kishida S; Cao D; Murakami-Tonami Y; Mu P; Nakaguro M; Koide N; Takeuchi I; Onishi A; Kadomatsu K
Cancer Res; 2011 Apr; 71(8):2938-48. PubMed ID: 21349947
[TBL] [Abstract][Full Text] [Related]
3. Combinational antitumor effect of siRNA against midkine and paclitaxel on growth of human prostate cancer xenografts.
Takei Y; Kadomatsu K; Goto T; Muramatsu T
Cancer; 2006 Aug; 107(4):864-73. PubMed ID: 16832814
[TBL] [Abstract][Full Text] [Related]
4. Disruption of cooperation between Ras and MycN in human neuroblastoma cells promotes growth arrest.
Yaari S; Jacob-Hirsch J; Amariglio N; Haklai R; Rechavi G; Kloog Y
Clin Cancer Res; 2005 Jun; 11(12):4321-30. PubMed ID: 15958613
[TBL] [Abstract][Full Text] [Related]
5. Midkine and Alk signaling in sympathetic neuron proliferation and neuroblastoma predisposition.
Reiff T; Huber L; Kramer M; Delattre O; Janoueix-Lerosey I; Rohrer H
Development; 2011 Nov; 138(21):4699-708. PubMed ID: 21989914
[TBL] [Abstract][Full Text] [Related]
6. Prolonged N-myc protein half-life in a neuroblastoma cell line lacking N-myc amplification.
Cohn SL; Salwen H; Quasney MW; Ikegaki N; Cowan JM; Herst CV; Kennett RH; Rosen ST; DiGiuseppe JA; Brodeur GM
Oncogene; 1990 Dec; 5(12):1821-7. PubMed ID: 2284101
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic targeting of TLR9 inhibits cell growth and induces apoptosis in neuroblastoma.
Brignole C; Marimpietri D; Di Paolo D; Perri P; Morandi F; Pastorino F; Zorzoli A; Pagnan G; Loi M; Caffa I; Erminio G; Haupt R; Gambini C; Pistoia V; Ponzoni M
Cancer Res; 2010 Dec; 70(23):9816-26. PubMed ID: 20935225
[TBL] [Abstract][Full Text] [Related]
8. Plasma midkine level is a prognostic factor for human neuroblastoma.
Ikematsu S; Nakagawara A; Nakamura Y; Ohira M; Shinjo M; Kishida S; Kadomatsu K
Cancer Sci; 2008 Oct; 99(10):2070-4. PubMed ID: 19016768
[TBL] [Abstract][Full Text] [Related]
9. Cell lineage and differentiation state are primary determinants of MYCN gene expression and malignant potential in human neuroblastoma cells.
Spengler BA; Lazarova DL; Ross RA; Biedler JL
Oncol Res; 1997; 9(9):467-76. PubMed ID: 9495452
[TBL] [Abstract][Full Text] [Related]
10. N-myc regulation of type I insulin-like growth factor receptor in a human neuroblastoma cell line.
Chambéry D; Mohseni-Zadeh S; de Gallé B; Babajko S
Cancer Res; 1999 Jun; 59(12):2898-902. PubMed ID: 10383152
[TBL] [Abstract][Full Text] [Related]
11. Myc promotes glutaminolysis in human neuroblastoma through direct activation of glutaminase 2.
Xiao D; Ren P; Su H; Yue M; Xiu R; Hu Y; Liu H; Qing G
Oncotarget; 2015 Dec; 6(38):40655-66. PubMed ID: 26528759
[TBL] [Abstract][Full Text] [Related]
12. Coactivation of the MDR1 and MYCN genes in human neuroblastoma cells during the metastatic process in the nude mouse.
Ferrandis E; Da Silva J; Riou G; Bénard I
Cancer Res; 1994 Apr; 54(8):2256-61. PubMed ID: 8174136
[TBL] [Abstract][Full Text] [Related]
13. Midkine induces epithelial-mesenchymal transition through Notch2/Jak2-Stat3 signaling in human keratinocytes.
Huang Y; Hoque MO; Wu F; Trink B; Sidransky D; Ratovitski EA
Cell Cycle; 2008 Jun; 7(11):1613-22. PubMed ID: 18469519
[TBL] [Abstract][Full Text] [Related]
14. Midkine enhances soft-tissue sarcoma growth: a possible novel therapeutic target.
Jin Z; Lahat G; Korchin B; Nguyen T; Zhu QS; Wang X; Lazar AJ; Trent J; Pollock RE; Lev D
Clin Cancer Res; 2008 Aug; 14(16):5033-42. PubMed ID: 18698021
[TBL] [Abstract][Full Text] [Related]
15. Notch2-induced COX-2 expression enhancing gastric cancer progression.
Tseng YC; Tsai YH; Tseng MJ; Hsu KW; Yang MC; Huang KH; Li AF; Chi CW; Hsieh RH; Ku HH; Yeh TS
Mol Carcinog; 2012 Dec; 51(12):939-51. PubMed ID: 21976141
[TBL] [Abstract][Full Text] [Related]
16. TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance.
Shimada H; Nakagawa A; Peters J; Wang H; Wakamatsu PK; Lukens JN; Matthay KK; Siegel SE; Seeger RC
Cancer; 2004 Oct; 101(8):1873-81. PubMed ID: 15386308
[TBL] [Abstract][Full Text] [Related]
17. Notch2 signaling is required for potent antitumor immunity in vivo.
Sugimoto K; Maekawa Y; Kitamura A; Nishida J; Koyanagi A; Yagita H; Kojima H; Chiba S; Shimada M; Yasutomo K
J Immunol; 2010 May; 184(9):4673-8. PubMed ID: 20351182
[TBL] [Abstract][Full Text] [Related]
18. Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes.
Warnat P; Oberthuer A; Fischer M; Westermann F; Eils R; Brors B
BMC Cancer; 2007 May; 7():89. PubMed ID: 17531100
[TBL] [Abstract][Full Text] [Related]
19. MYCN-related suppression of functional CD44 expression enhances tumorigenic properties of human neuroblastoma cells.
Gross N; Balmas Bourloud K; Brognara CB
Exp Cell Res; 2000 Nov; 260(2):396-403. PubMed ID: 11035936
[TBL] [Abstract][Full Text] [Related]
20. Notch2 signaling induces apoptosis and inhibits human MDA-MB-231 xenograft growth.
O'Neill CF; Urs S; Cinelli C; Lincoln A; Nadeau RJ; León R; Toher J; Mouta-Bellum C; Friesel RE; Liaw L
Am J Pathol; 2007 Sep; 171(3):1023-36. PubMed ID: 17675579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
